Crofelemer has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency for SBS and MVID. In October 2025, as announced, the company ...
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – Genomics-driven cancer diagnostics are accelerating market growth, with the genomics in cancer care market ...
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of ...
19hon MSN
A CT hospital is expanding a program that is saving lives. Here’s how it works, why it was adopted
Use of whole blood products to save egregiously injured U.S. military combatants became a practice during wars in Iraq and ...
Sobi® (STO: SOBI) today announced that topline results from the Phase 2a EMBRACE study evaluating Gamifant® (emapalumab) for ...
The FDA expanded the approval of Cablivi to include pediatric patients 12 years and older with acquired thrombotic thrombocytopenic purpura.
The Food and Drug Administration has approved Yartemlea ® (narsoplimab-wuug) for the treatment of adult and pediatric patients aged 2 years and older with hematopoietic stem cell transplant ...
Sobi (STO: SOBI) today announced that topline results from the Phase 2a EMBRACE study evaluating Gamifant (emapalumab) for interferon-gamma (IFN?)-driven ...
Introduction Cancer care in humanitarian settings is very challenging, and patients may face significant barriers to ...
The new Phase III study will test calderasib in a chemo-free regimen for G12C-mutated patients regardless of PD-L1 status.
Matthew Hurley experienced frustration when trying to access PrEP to prevent HIV, due to a lack of knowledge from his doctor and incorrect bills from his insurance provider, highlighting the need for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback